4.7 Article

Isoliquiritigenin ameliorates dextran sulfate sodium-induced colitis through the inhibition of MAPK pathway

Journal

INTERNATIONAL IMMUNOPHARMACOLOGY
Volume 31, Issue -, Pages 223-232

Publisher

ELSEVIER
DOI: 10.1016/j.intimp.2015.12.024

Keywords

Isoliquiritigenin; Inflammatory bowel disease; MAPK inhibition; Colon

Funding

  1. GRRC program of Gyeonggi province [GRRC-DONGGUK2015-B01]
  2. Agricultural Biotechnology Development Program [114071-3]
  3. Ministry of Agriculture, Food and Rural Affairs
  4. Korean Health Technology R&D Project through the Korean Health Industry Development Institute (KHIDI) [HI14C0556]
  5. Ministry of Health & Welfare, Republic of Korea

Ask authors/readers for more resources

Isoliquiritigenin (isoLQ), a chalcone found in licorice, has shown a variety of biological activity including antiinflammatory and antioxidative effects, and the distribution of isoLQ in gastrointestinal tract was higher than any other tissues. Thus, we evaluated whether or not isoLQ attenuated the dextran sulfate sodium (DSS)-induced colitis by observing the physiological changes (body weight loss, diarrhea, bleeding stool, overall disease activity index (DAI) scores, colon length), histopathological analysis and myeloperoxidase (MPO) activities of esophagus and colon. Also, the MAPK pathways including phosphorylation of ERK1/2, p38, and AKT, and the activation of NK-kappa B were evaluated in colon tissue. Interestingly, the reduction of body weight and colon length, increase of diarrhea, bloody stool, DAI scores and MPO activity, and histologic disturbances in DSS-induced colitis were recovered by isoLQ treatment. Also, isoLQ treatment suppressed the phosphorylation of ERK1/2 and p38, and the activation of NK-kappa B compared to those in DSS-induced colitis mice. In addition, the distributions of isoLQ in colon were relatively higher in DSS-induced colitis models. All of these results suggested that isoLQ has potential activity to ameliorate the DSS-induced colitis through the inhibition of MAPK pathway. (C) 2015 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available